SNDY Is Looking Pretty Again, Up To 100% Upside To The 50 DMA
Good Evening!
Solos Endoscopy, Inc. (OTCPINK: SNDY)
SNDY has been very generous to traders this year and I’ve looked carefully at the play and believe that it is about to issue another round of gain potential -- the first big rally for May and you are getting a chance to move before everyone else does.
This is how things have panned out for the company over the last few months. In February SNDY delivered one of its biggest one-day performances, rising from an open of .09 to a high of .15 for gains of up to 66%.
February saw sporadic breakouts but the next biggest delivery came on March 1 when SNDY opened at .10 and rallied to a high of .13 for gains of up to 30%. The rallies from then on were smaller but April 18 saw a major spike; SNDY rocketed from an open of .04 to a .06 high. This delivered one-day gains of up to 50%.
Now it’s May and I believe there is potential for much larger spikes. The bullish near term outlook is based partly on the fact that SNDY has undergone considerable consolidation over the last few weeks. So far May has produced none of the patterned breakouts delivered in other months which make the current chart a good gauge for urgent entry.
Basically, you are looking at play positioned from bottom – RSI is 34 on the daily chart and daily volatility levels are looking skyward.
The dirt cheap entry of around .02 should be a major catalyst for action right now. This is especially so when you consider that the 4-week high of .06 suggests upside opportunity of around 200%.
In other words, the potential upside currently offered by SNDY is greater than the aforementioned breakouts combined!
Here’s a link to the chart: http://www.barchart.com/interactive_charts/stocks/SNDY
About
SNDY (Solos Endoscopy, Inc.) is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office.
US Medical Device Market On Track For $133 Billion In 2016
The United States remains the largest medical device market in the world with a market size of around $110 billion, and it is expected to reach $133 billion by 2016.
The U.S. market value represented about 38 percent of the global medical device market in 2012. U.S. exports of medical devices in key product categories identified by the Department of Commerce (DOC) exceeded $44 billion in 2012, a more than 7 percent increase from the previous year.
News Development
Solos Endoscopy Fulfills Backorders for MammoView(R) Ductoscopy Instruments
SNDY has resumed sales of its MammoView® Ductoscopy Instruments as a result of its ability to fulfil all of its backorders, which were due to production issues experienced from one of its component manufacturers. The component manufacturer has resolved its production issue and has resumed its deliveries, on a timely basis, to Solos and is confident that it will not experience this issue in the future.
"The production issues have been successfully addressed and I'm confident in the uninterrupted sale and production of the MammoView® product line going forward," stated Robert Segersten, CEO.
Solos Endoscopy, Inc. FDA Establishment Registration & Device Listing Renewed for 2016
SNDY has also renewed the Establishment Registration & Device Listing of its endoscopic instruments with the U.S. Food and Drug Administration (FDA).
Solos Endoscopy instruments are registered and approved with the FDA; the FDA approval also covers the entire MammoView® instrument line. The company markets over 200 items to the endoscopic market and is continuing the development of products that will enhance the ability of medical professionals to perform minimally invasive surgical techniques.
To learn more about SNDY please visit their website: http://www.solosendoscopy.com/
SNDY is primed again for another round of gain potential; you’ve seen it play out in the charts so make your move ASAP.
